Early trial of experimental cancer combo halted after just 6 patients
NCT ID NCT06870487
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after enrolling only 6 participants. Because it was stopped, we have very limited information on how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-08046032 (a new drug given by IV) and sasanlimab (an immunotherapy given as a shot)
What this could lead to
If it works, this could point toward a new treatment option for certain advanced cancers that have not responded to standard therapies.
What could go wrong
This was a very early Phase 1 trial with only 6 participants and was terminated early, so results are limited. The drug may not prove safe or effective in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutchinson Cancer Center.
Seattle, Washington, 98109, United States
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
University of Washington Medical Center- Montlake
Seattle, Washington, 98195, United States